Higher vitamin D in midlife linked to less brain tau later

Tau protein is one of the brain’s most watched troublemakers in dementia research because it builds into tangles that are closely tied to neuronal injury and cognitive decline. In a Framingham Heart Study analysis published April 1, 2026, higher vitamin D levels in midlife were linked to less tau burden years later, a result that points to a possible prevention window without showing that supplements alone will stop dementia.

Martin David Mulligan and colleagues followed 793 dementia-free Framingham Heart Study Generation 3 participants whose serum 25-hydroxyvitamin D was measured during examination cycle 1 from 2002 to 2005. The group had a mean age of 39 years, plus or minus 8 years, when blood was drawn, and brain PET imaging was completed between 2016 and 2019, after an average gap of 16 years, plus or minus 2 years. Higher serum 25(OH)D was associated with lower global tau-PET deposition and lower composite tau-PET deposition. Vitamin D was not associated with amyloid-PET burden, which matters because amyloid and tau do not always move together in the brain.

The study defined high vitamin D as greater than 30 ng/mL. Even in this relatively young cohort, 34% of participants had low vitamin D levels and 5% were taking vitamin D supplements. The analysis adjusted for age, sex, depression, season, smoking, systolic blood pressure, antihypertensive medication use, diabetes, cardiovascular disease and body mass index, which strengthens the case that the signal was not just a reflection of general health differences. The paper says low vitamin D in midlife may represent a potentially modifiable target to mitigate preclinical dementia signs.

The key nuance is where this finding sits on the evidence ladder. The study showed an association, not proof that raising vitamin D now will directly lower tau or prevent dementia later, and vitamin D was measured only once. That distinction matters in a field where the US Preventive Services Task Force said in 2021 that evidence is insufficient to assess the benefits and harms of screening asymptomatic adults for vitamin D deficiency. Still, the result lands in a country where the Centers for Disease Control and Prevention says vitamin D deficiency affects about 10% of the general population and as many as 31% of non-Hispanic Black adults.

Framingham gives the finding added weight. The study began in 1948 in Framingham, Massachusetts, expanded to the Offspring cohort in 1971 and the Third Generation cohort in 2002, and has become one of the deepest reservoirs of data on cardiovascular disease, stroke, biomarkers and brain aging. In that long arc, the new tau signal looks less like a prescription and more like a clue: midlife may be the moment when a small nutritional difference starts to matter.